Cellular and Molecular Mechanisms Underly the Combined Treatment of Fasudil and Bone Marrow Derived-Neuronal Stem Cells in a Parkinson's Disease Mouse Model

Mol Neurobiol. 2023 Apr;60(4):1826-1835. doi: 10.1007/s12035-022-03173-y. Epub 2022 Dec 29.

Abstract

Bone marrow-derived neural stem cells (BM-NSCs) have shed light on novel therapeutic approaches for PD with the potential to halt or even reverse disease progression. Various strategies have been developed to promote therapeutic efficacy via optimizing implanted cells and the microenvironment of transplantation in the central nervous system (CNS). This current study further proved that the combination of fasudil, a Rho-kinase inhibitor, and BM-NSCs exhibited a synergetic effect on restoring neuron loss in the MPTP-PD mice model. It simultaneously unveiled cellular mechanisms underlying synergistic neuron-protection effects of fasudil and BM-NSCs, which included promoting the proliferation, and migration of endogenous NSCs, and contributing to microglia shift into the M2 phenotype. Corresponding molecular mechanisms were observed, including the inhibition of inflammatory responses, the elevation of neurotrophic factors, and the induction of WNT/β-catenin and PI3K/Akt/mTOR signaling pathways. Our study provides evidence for the co-intervention of BM-NSCs and fasudil as a promising therapeutic method with enhanced efficacy in treating neurodegenerative diseases.

Keywords: Bone marrow-neural stem cells; Fasudil; MPTP-PD model; Parkinson’s Disease.

MeSH terms

  • Animals
  • Bone Marrow
  • Bone Marrow Cells
  • Mice
  • Neural Stem Cells* / metabolism
  • Neurons
  • Parkinson Disease* / metabolism
  • Phosphatidylinositol 3-Kinases / metabolism

Substances

  • fasudil
  • Phosphatidylinositol 3-Kinases